首过灌注心脏磁共振对癌症相关心脏肿块的预后风险分层增量价值
本研究纳入462例癌症患者,评估首过灌注心脏磁共振对心脏肿块血管性的诊断与预后价值。灌注参数中对比剂摄取率鉴别心脏转移与血栓的AUC为0.89-0.93,优于对比增强率(AUC 0.66-0.72)。在LGE-CMR定义的心脏转移患者中,灌注对比增强率最低三分位组死亡风险最高(P=0.002),提示灌注磁共振可为LGE-CMR提供补充预后信息。
要点
- 对比剂摄取率鉴别心脏转移与血栓的AUC为0.89-0.93,优于对比增强率(AUC 0.66-0.72)。
- LGE-CMR定义的心脏转移患者中,灌注对比增强率最低三分位组死亡率最高(P=0.002)。
- 灌注磁共振评估的心脏转移患者死亡率高于对照(HR 1.42,95%CI 1.06-1.90;P=0.02)。
核心结论
- 首过灌注心脏磁共振提供补充LGE-CMR的预后价值:在LGE-CMR定义的心脏转移癌症患者中,死亡率随病灶低灌注程度增加而升高。
研究设计与样本
- 成人癌症患者伴心脏肿块行CMR检查,其中心脏转移173例、心脏血栓69例,并与癌症类型/分期匹配的无心脏肿块对照比较;首过灌注CMR视觉与半定量评估血管性,随访全因死亡率。
诊断标准与关键数值
- 对比剂摄取率(斜率)鉴别LGE-CMR证实的转移与血栓的AUC为0.89-0.93,对比增强率(平台/基线)的AUC为0.66-0.72;对比剂摄取率(P=0.10)和对比增强率(P=0.01)通常误分类轻微强化的心脏转移。
临床应用与阅片要点
- 对癌症患者心脏肿块,可结合首过灌注CMR评估血管性;半定量灌注证实的转移患者死亡率高于对照(HR 1.42,95%CI 1.06-1.90;P=0.02),视觉灌注(HR 1.47,95%CI 1.12-1.94;P=0.006)和LGE-CMR(HR 1.52,95%CI 1.16-2.00;P=0.003)结果平行。
局限性
- 对比剂摄取率(P=0.10)和对比增强率(P=0.01)通常误分类轻微强化的心脏转移。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiac magnetic resonance (CMR) differentiates cardiac metastasis (CMET) and cardiac thrombus (CTHR) based on tissue characteristics stemming from vascularity on late gadolinium enhancement (LGE). Perfusion CMR can assess magnitude of vascularity; utility for cardiac masses (CMASS) is unknown.
OBJECTIVES: This study sought to determine if perfusion CMR provides diagnostic and prognostic utility for CMASS beyond binary differentiation of CMET and CTHR.
METHODS: The population comprised adult cancer patients with CMASS on CMR; CMET and CTHR were defined using LGE-CMR: CMASS+ patients were matched to CMASS- control subjects for cancer type/stage. First-pass perfusion CMR was interpreted visually and semiquantitatively for CMASS vascularity, including contrast enhancement ratio (CER) (plateau vs baseline) and contrast uptake rate (CUR) (slope). Follow-up was performed for all-cause mortality.
RESULTS: A total of 462 cancer patients were studied, including patients with (CMET = 173, CTHR = 69) and without CMASS on LGE-CMR. On perfusion CMR, CER and CUR were higher within CMET vs CTHR (P < 0.001); CUR yielded better performance (AUC: 0.89-0.93) than CER (AUC: 0.66-0.72) (both P < 0.001) to differentiate LGE-CMR-evidenced CMET and CTHR, although both CUR (P = 0.10) and CER (P = 0.01) typically misclassified CMET with minimal enhancement. During follow-up, mortality among CMET patients was high but variable; 47% of patients were alive 1 year post-CMR. Patients with semiquantitative perfusion CMR-evidenced CMET had higher mortality than control subjects (HR: 1.42 [95% CI: 1.06-1.90]; P = 0.02), paralleling visual perfusion CMR (HR: 1.47 [95% CI: 1.12-1.94]; P = 0.006) and LGE-CMR (HR: 1.52 [95% CI: 1.16-2.00]; P = 0.003). Among patients with CMET on LGE-CMR, mortality was highest among patients (P = 0.002) with lesions in the bottom perfusion (CER) tertile, corresponding to low vascularity. Among CMET and cancer-matched control subjects, mortality was equivalent (P = NS) among patients with lesions in the upper CER tertile (corresponding to higher lesion vascularity). Conversely, patients with CMET in the middle (P = 0.03) and lowest (lowest vascularity) (P = 0.001) CER tertiles had increased mortality.
CONCLUSIONS: Perfusion CMR yields prognostic utility that complements LGE-CMR: Among cancer patients with LGE-CMR defined CMET, mortality increases in proportion to magnitude of lesion hypoperfusion.
引用
- Chan, Maya, Park, et al. Incremental Utility of First-Pass Perfusion CMR for Prognostic Risk Stratification of Cancer-Associated Cardiac Masses. JACC Cardiovasc Imaging. 2023. PMID: 37410010. doi:10.1016/j.jcmg.2023.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。